RecruitingPhase 2NCT07560488

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

Studying Adult hepatocellular carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Intervention
Bevacizumab Biosimilar IBI305(drug)
Enrollment
43 target
Eligibility
18-75 years · All sexes
Timeline
20262028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07560488 on ClinicalTrials.gov

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Adult hepatocellular carcinoma

← Back to all trials